Paclitaxel Regulates TRPA1 Function and Expression Through PKA and PKC.

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Paclitaxel (PTX) is a vital chemotherapy drug known to induce peripheral neuropathy.
• The Transient Receptor Potential Ankyrin 1 (TRPA1) channel is implicated in the toxicity of chemotherapy agents.
• The specific impact of PTX on TRPA1's functional expression and calcium currents remains unclear.

Purpose of the Study:

• To investigate the effect of Paclitaxel (PTX) on the functional expression and activity of the TRPA1 channel in a neuronal cell line.
• To elucidate the role of TRPA1 in PTX-induced neuropathy mechanisms.

Main Methods:

• Quantitative PCR and Western blot analyses were used to assess TRPA1 mRNA and protein expression levels.
• Calcium imaging techniques were employed to measure PTX-induced changes in intracellular calcium concentrations and TRPA1-mediated currents.
• Specific TRPA1 agonist (AITC) and antagonist (HC-030031) were used to confirm TRPA1 involvement.
• Inhibitors of PKA, PKC, and PI3K signaling pathways were utilized to explore regulatory mechanisms.

Main Results:

• PTX significantly increased both mRNA and protein expression of TRPA1.
• PTX exposure led to enhanced TRPA1-mediated calcium currents and intracellular calcium concentrations.
• The observed effects of PTX on TRPA1 were dependent on the TRPA1 agonist and were blocked by the antagonist.
• Inhibition of PKA and PKC signaling pathways attenuated PTX's effect on TRPA1 functional expression, while PI3K inhibition had no effect.

Conclusions:

• Paclitaxel-induced peripheral neuropathy involves TRPA1 channel activity, characterized by increased functional expression.
• The regulation of PTX-induced TRPA1 activity is mediated by Protein Kinase A (PKA) and Protein Kinase C (PKC) signaling pathways.
• These findings highlight the TRPA1 channel as a potential therapeutic target for mitigating PTX-induced neuropathy.